AJCN EB Program 2010
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gross, M.
Right arrow Articles by Jacobs, D. R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gross, M.
Right arrow Articles by Jacobs, D. R, Jr
Agricola
Right arrow Articles by Gross, M.
Right arrow Articles by Jacobs, D. R
American Journal of Clinical Nutrition, Vol. 77, No. 2, 458-466, February 2003
© 2003 American Society for Clinical Nutrition


Original Research Communication

Lipid standardization of serum fat-soluble antioxidant concentrations: the YALTA study1,2,3

Myron Gross, Xinhua Yu, Peter Hannan, Christian Prouty and David R Jacobs, Jr

1 From the Department of Laboratory Medicine and Pathology, School of Medicine (MG), and the Division of Epidemiology, School of Public Health (XY, PH, CP, and DRJ), University of Minnesota, Minneapolis.

2 Supported by grant no. 1RO1-HL53560-01A1 from the National Heart, Lung, and Blood Institute.

3 Address reprint requests to M Gross, Department of Laboratory Medicine and Pathology, School of Medicine, University of Minnesota, Mayo Mail Code 609, 420 Delaware Street Southeast, Minneapolis, MN 55455. E-mail: gross{at}epi.umn.edu.


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Background: Blood lipids can influence fat-soluble antioxidant concentrations and confound their interpretation as indicators of antioxidant intake status and disease risk.

Objectives: The objectives were to identify lipoproteins that can confound the interpretation of serum fat-soluble antioxidants, to evaluate the amount of the confounding, and to recommend a method for standardizing blood concentrations of fat-soluble antioxidants.

Design: Several methods of lipid standardization of fat-soluble antioxidants were evaluated in a large cohort of young adults with the use of both cross-sectional and longitudinal data analysis.

Results: Tocopherol and carotenoid concentrations were associated with plasma total cholesterol and its components, LDL, HDL, and VLDL cholesterol (estimated as plasma total triacylglycerols/5), some of which were independent predictors for all of the fat-soluble antioxidants. Among supplement nonusers, the most amphipathic (polar) of the antioxidants ({alpha}-tocopherol, {gamma}-tocopherol, and zeaxanthin plus lutein) and lycopene were associated strongly with these lipid fractions (R2 = 0.09, 0.40). Consistent with a causal association in which blood antioxidant concentrations change as blood lipid concentrations change, similar relations were found for changes in blood antioxidant and lipid concentrations over a 7-y period. Concentrations of the remaining carotenoids (ß-cryptoxanthin, {alpha}-carotene, and ß-carotene) had a weaker association with plasma lipoproteins (R2 < 0.06). Similar relations were found for supplement users.

Conclusions: The simultaneous adjustment of the concentrations of tocopherols, zeaxanthin plus lutein, and lycopene for VLDL, HDL, and LDL cholesterol is recommended. This method is practical and can provide a basis for the standardization of carotenoid and tocopherol concentrations.

Key Words: Serum antioxidant concentration • blood lipids • lipid standardization • lipoproteins • total cholesterol • fat-soluble vitamins • young adults


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Several carotenoids and tocopherols act in the maintenance of essential cellular functions and are classified as vitamins or precursors of vitamins. In addition to these well-established functions (1, 2), the fat-soluble compounds have antioxidant activities and have been associated with the prevention of lipid peroxidation and chronic diseases (39), but they have had little effect in most clinical trials to date (1013). A critical aspect of an evaluation of these activities is the assessment of the carotenoid and tocopherol status in human subjects. Generally, status has been assessed by a measurement of carotenoid and tocopherol concentrations in blood, without or with an adjustment for a limited set (1 or 2) of blood lipids. This approach provides an indication of status, but it has a significant limitation, in that antioxidant concentrations in blood are influenced by the concentrations of most blood lipids rather than of a single component (14, 15). Differences in blood lipid concentrations can confound the interpretation of antioxidant concentrations (16, 17). Even partial adjustment for lipids has been shown to improve estimates of antioxidant intake (15, 18, 19), status (14, 16, 17), and associations with disease (20, 21), and lipid adjustments have been incorporated into many studies (2225). Our goal is identification of a more complete set of plasma lipids and lipoproteins, which contribute to the variation in antioxidant concentrations in human populations and define adjustments for the standardization of antioxidant concentrations.

Tocopherol and carotenoid concentrations have been associated with concentrations of total cholesterol, phospholipid, triacylglycerol, lipoprotein, and apolipoprotein in blood (14, 20, 21, 2628). Several methods have been used to reduce the confounding of antioxidants with blood lipid concentrations (21, 29, 30). Each of these methods has significant limitations (31).

We hypothesize that each blood lipoprotein uniquely influences serum concentrations of fat-soluble antioxidants. Moreover, a lipid standardization of antioxidant concentrations that involves HDL, LDL, and VLDL (each represented by its cholesterol concentration) separately will be more indicative of the antioxidant status in human populations than will a cumulative measure of lipoproteins, such as total cholesterol.

With the use of data from the Young Adults Longitudinal Trends in Antioxidants (YALTA) study [an ancillary study of the Coronary Artery Risk Development in Young Adult (CARDIA) study], analyses were performed to further define the influence of blood lipids on fat-soluble antioxidant concentrations. Specifically, we evaluated associations between 7 serum fat-soluble antioxidants and the fasting concentrations of total, LDL, HDL, and VLDL cholesterol; apolipoprotein (apo) B; and apo A-I in this population-based setting.


    SUBJECTS AND METHODS
 TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The YALTA study measured serum antioxidant concentrations in frozen samples as an ancillary study to the CARDIA study, which is a longitudinal cohort study that has tracked the evolution of cardiovascular disease risk factors in human subjects beginning at age 18–30 y. In 1985 and 1986, black and white men and women (n = 5115) were recruited in Birmingham, AL; Chicago; Minneapolis; and Oakland, CA (32). Recruitment was population-based, and subjects were recruited at random by telephone or door-to-door contact in the first 3 cities and at random from members of the large Kaiser Permanente Medical Care Plan in Oakland. The overall response rate was {approx}50% (33). By design, the sample in each of the 4 cities was balanced by race (black or white), sex, age (18–24 y compared with 25–30 y), and educational level (high school or less compared with at least some college), and approximately equal numbers of subjects were recruited from each site (34). Participants were reexamined during follow-up at years 2, 5, 7, and 10. Most of the surviving cohort (78.5%) participated in the year 10 examination, between June 1995 and June 1996. Higher rates of participation occurred in years 2, 5, and 7 than in year 10 (35). All participants in the CARDIA baseline examination were included in this study, except 147 who were not fasting for at least 8 h and those with insufficient quantities of stored blood. The number of participants in each part of the analysis is specified in the tables.

Blood samples were drawn after an overnight fast by venipuncture into evacuated tubes. The plasma was separated by centrifugation, transferred into airtight vials, and stored at -70°C until it was shipped on dry ice to the Northwest Lipid Research Laboratories, University of Washington, Seattle. Total cholesterol and triacylglycerols were measured enzymatically within 6 wk of collection (36). HDL cholesterol was measured after the precipitation of LDL containing lipoproteins with dextran sulfate and magnesium chloride (37). LDL cholesterol was calculated with the use of the equation of Friedewald et al (38). Radioimmunoassays were performed to measure apo A-I and apo B-100 (39). The technical error, reported previously (20), was 3.3% for total cholesterol, 3.9% for HDL cholesterol, 8.4% for triacylglycerols, 7.0% for apo A-I, and 8.6% for apo B.

In the YALTA study carried out between 1995 and 1998 at the Molecular Epidemiology and Biomarker Research Laboratory, University of Minnesota, serum antioxidant vitamins were measured. The sera for {alpha}- and {gamma}-tocopherol analysis and analysis of the carotenoids {alpha}- and ß-carotene, lycopene, zeaxanthin plus lutein, and ß-cryptoxanthin were from CARDIA study years 0 and 7 and were stored at -70°C. The tocopherols and carotenoids were measured with an HPLC-based assay. The assay was a modification of the method of Bieri et al (40) with calibration as described by Craft et al (41) and sample handling as described by Gross et al (42). The primary modification was the simultaneous detection of tocopherols and carotenoids. The {alpha}- and {gamma}-tocopherols were detected by the use of a second absorbance channel set at 292 nm. The retention time of {alpha}- and {gamma}-tocopherol was 5.0 and 4.5 min, respectively. Other modifications were the addition of diisopropylethylamine (0.015%) in the HPLC solvent as an aid to analyte recovery and the use of tocol, rather than tocopherol acetate, as an internal standard for tocopherols. Calibration was performed with pure compounds (Hoffman-LaRoche, Basel, Switzerland; Sigma Chemical Co, St Louis). Quality-control procedures included routine analysis of plasma and serum control pools containing high and low concentrations of each analyte. In addition, the laboratory routinely analyzed National Institutes of Standards and Technology reference sera and was a participant in the National Institutes of Standards and Technology Fat-Soluble Vitamin Quality Assurance Group. The CVs were <10% for all analytes and control pools. Previously, we showed that the intraclass correlation coefficients (ratio of between-person variance to between- plus within-person variance) were 0.93 for {alpha}-carotene, 0.98 for ß-carotene, 0.73 for zeaxanthin plus lutein, 0.97 for ß-cryptoxanthin, 0.73 for lycopene, and 0.93 for {alpha}-tocopherol (20).

Results are presented separately for nonusers and users of supplements. A supplement user was defined as any person consuming vitamins A, E, and C in excess of his or her intake from foods alone. The source of vitamin A in many of the supplements includes {alpha}- and ß-carotene. In the analysis, all findings were similar after adjustment or stratification for race and sex (data not shown). Thus, unadjusted findings are presented.

Cross-sectional analyses used data only from the baseline (year 0) of the CARDIA study. To assess the general pattern of association of antioxidants with plasma lipids, the mean level of each antioxidant was plotted according to 20 categories of total cholesterol. After the exclusion of missing data, each one-twentieth contained {approx}240 people. This procedure was repeated for one-twentieths of concentrations of LDL, HDL, and VLDL cholesterol; apo A-I; and apo B. The correlation coefficient (r) is calculated on individual data, and P values and coefficients are reported for each analysis. Because of our conceptual interest in lipoprotein cholesterol fractions, we estimated VLDL cholesterol as total triacylglycerols divided by 5, an estimate based on the equation of Friedewald et al (38). Thus, the results for triacylglycerols exactly parallel those for VLDL cholesterol.

With multiple linear regression, each serum antioxidant vitamin was analyzed as a dependent variable on lipoprotein characteristics by the use of a series of models. Model 1 contained only plasma total cholesterol as an independent variable. Model 2 had only plasma LDL cholesterol; model 3 had plasma total cholesterol and VLDL cholesterol; model 4 had plasma LDL, HDL, and VLDL cholesterol simultaneously. Note that because total cholesterol is the sum of LDL, HDL, and VLDL cholesterol, model 1 differs from model 4 only in that the 3 lipoprotein cholesterol fractions have a common coefficient in model 1, whereas they have different coefficients in model 4. Model 5 used regression to analyze the change in antioxidant concentrations (year 7 - year 0) on the corresponding changes in LDL, HDL, and VLDL cholesterol. This last model evaluated the within-person associations of changes in serum antioxidant concentrations with changes in lipoprotein concentrations. Two additional models included only apo A-I and apo B-100, and the 5 independent variables—LDL, HDL, and VLDL cholesterol; apo A-I; and apo B-100 (data not shown). In total, 49 regression analyses were run (7 antioxidants each with 7 combinations of independent variables). In the regression models, antioxidants are expressed in micromolar concentrations and lipoprotein cholesterols in millimolar concentrations. Cross-sectional models (14) were evaluated by the conditional F test that compares the R2 in nested models. To evaluate the change in model 5 against the best cross-sectional model (model 4), we used repeated-measures data for years 0 and 7 of the study. We compared 2 additional models: the first model used separate coefficients for the cross-sectional and change components for each lipoprotein fraction, and the second model used these component coefficients pooled. We tested the difference between these two models with the log-likelihood ratio test based on 3 df. Statistical analyses were performed with SAS software, versions 6, 12, and beyond (SAS Institute, Inc, Cary, NC).


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
General description
Lipid and antioxidant measurements were obtained from >92% of all CARDIA study participants. Approximately one-third (30%) of persons in the population were users of vitamin supplements. A multivitamin or other combination containing vitamins A, E, and C was taken by 63% of the supplement users. The use of a vitamin C (a nonfat-soluble antioxidant vitamin) supplement alone qualified a person as a supplement user because vitamin C actively regenerates vitamin E and may spare lipid-soluble antioxidants in general. As shown in Table 1Go, antioxidant concentrations were 7–49% higher in supplement users than in supplement nonusers, with the exceptions of {gamma}-tocopherol and lycopene concentrations, which were, respectively, 14% and 5% lower. The difference in mean plasma lipid concentrations between supplement users and supplement nonusers was <0.03879 mmol/L (<3%) for total, VLDL, HDL, and LDL cholesterol and was statistically significant only for HDL cholesterol.


View this table:
[in this window]
[in a new window]
 
TABLE 1 . Characteristics of participants according to vitamin supplement use at year 0 (1985–1986) of the CARDIA study1
 
Linear association
The cholesterol and lipoproteins of plasma were major correlates of the fat-soluble antioxidants (Figure 1Go). For instance, serum tocopherol and carotenoid concentrations were higher in persons with high LDL cholesterol than in those with low LDL cholesterol. Each antioxidant has a linear relation with the LDL-cholesterol concentration on its natural scale, even in the lowest and highest 5% of the sample. The slopes of the relations were steepest for the antioxidants occurring at the highest concentrations and lowest for those occurring at the lowest concentrations, ie, {gamma}-tocopherol and {alpha}-carotene. Associations between each antioxidant and serum total and HDL cholesterol (data not shown) were similar to the association between each antioxidant and LDL cholesterol, with the modification that the associations with HDL cholesterol were less pronounced than those with total and LDL cholesterol.



View larger version (25K):
[in this window]
[in a new window]
 
FIGURE 1. . Relations between serum antioxidant and LDL concentrations. For {alpha}- and {gamma}-tocopherol, n = 4568; for carotenoids, n = 4550. Each point represents the mean value for 1/20th of the population. A: {alpha}-tocopherol, {diamond}; {gamma}-tocopherol, {square}. B: zeaxanthin, {diamond}; cryptoxanthin, {square}; lycopene, {triangleup}. C: {alpha}-carotene, {diamond}; ß-carotene, {square}.

 
Several of the serum antioxidants have a positive linear relationship with VLDL cholesterol concentrations, even in the lowest and highest 5% of the sample (Figure 2Go). A negative linear slope is found with the remaining antioxidants (ß-cryptoxanthin, lycopene, {alpha}-carotene, and ß-carotene).



View larger version (29K):
[in this window]
[in a new window]
 
FIGURE 2. . Relations between serum antioxidant and VLDL concentrations. For {alpha}- and {gamma}-tocopherol, n = 4567; for carotenoids, n = 4549. Each point represents the mean value for 1/20th of the population. A: {alpha}-tocopherol, {diamond}; {gamma}-tocopherol, {square}. B: zeaxanthin, {diamond}; cryptoxanthin, {square}; lycopene, {triangleup}. C: {alpha}-carotene, {diamond}; ß-carotene, {square}.

 
Cross-sectional regression analyses
Each plasma antioxidant concentration was evaluated by regression on total cholesterol (model 1), on LDL cholesterol (model 2), on the combination of total and VLDL cholesterol (model 3), and on the combination of HDL, LDL, and VLDL cholesterol (model 4). Regression coefficients for models 3 and 4 are shown in Table 2Go (models 1 and 2 are not shown). The combination of LDL, HDL, and VLDL cholesterol concentrations (model 4) accounted for significantly (P <= 0.03) more of the variability in antioxidant concentrations than did total cholesterol (model 1), LDL cholesterol alone (model 2), or the combination of total and VLDL cholesterol (model 3) for all antioxidants, with minor exceptions. The exceptions were {gamma}-tocopherol, for which models 3 and 4 accounted for similar amounts of variation, and lycopene, for which models 1 and 4 accounted for similar amounts of variation. The combination of total and VLDL cholesterol concentrations (model 3) accounted for a large portion of the overall variation in antioxidant concentrations that are due to the lipoproteins and for more of the variability in antioxidant concentrations than did total cholesterol (model 1) and LDL cholesterol alone (model 2). The differences in R2 values between models 2 and 3 were significant (P < 0.001) in all comparisons except for lycopene. Model 1 explained more of the variance than did model 2, but less than did model 3. For comparison, the R2 values for each antioxidant in model 1 in supplement nonusers and users, respectively, were as follows: {alpha}-tocopherol, 0.330 and 0.187; {gamma}-tocopherol, 0.073 and 0.074; zeaxanthin, 0.074 and 0.053; ß-cryptoxanthin, 0.028 and 0.017; lycopene, 0.093 and 0.075; {alpha}-carotene, 0.010 and 0.000; and ß-carotene, 0.027 and 0.002. In model 3, these values were increased in supplement nonusers and users, respectively: {alpha}-tocopherol, 0.050 and 0.033; {gamma}-tocopherol, 0.037 and 0.006; zeaxanthin, 0.016 and 0.017; ß-cryptoxanthin, 0.032 and 0.023; lycopene, -0.003 and -0.005; {alpha}-carotene, 0.010 and 0.016; and ß-carotene, 0.033 and 0.038.


View this table:
[in this window]
[in a new window]
 
TABLE 2 . Associations between serum antioxidant vitamin concentrations and plasma cholesterol and lipoprotein concentrations in participants of the CARDIA study from year 0 (1985–1986, baseline) to year 7 (1992–1993)
 
The absolute R2 values for model 4 tended to be lower in the supplement users than in the nonusers (Table 2Go). This is most apparent for {alpha}-tocopherol, for which the R2 values were 0.23 and 0.40 (model 4) in the supplement users and nonusers, respectively. The differences in R2 values (model 4) between these groups for each antioxidant were highly significant (P <= 0.03) for all antioxidants except zeaxanthin plus lutein, ß-cryptoxanthin, and lycopene.

The model 4 R2 values differed widely between antioxidants in both the supplement user and nonuser groups. The most amphipathic (polar) antioxidants ({alpha}-tocopherol, {gamma}-tocopherol, and zeaxanthin plus lutein) and lycopene had the highest R2 values in both the supplement user and nonuser groups. The regression coefficients in the supplement nonusers (Table 2Go) ranged from a -0.087 µmol/L change to a 8.86 µmol/L change in antioxidant concentration, for a 1.0-mmol/L difference in plasma lipid. In the supplement users (Table 2Go), coefficients ranged from a -0.178 µmol/L change to an 11.17 µmol/L change in antioxidant concentration, for a 1.0-mmol/L difference in plasma lipid. The model 4 lipoprotein coefficients for supplement users and nonusers were generally highest for {alpha}-tocopherol, {gamma}-tocopherol, and lycopene.

For almost all antioxidants, each lipoprotein in model 4 had an independent association (P <= 0.02) with antioxidant concentrations. There were 3 exceptions: 1) VLDL cholesterol was unrelated to zeaxanthin plus lutein and {alpha}-carotene among supplement nonusers; 2) VLDL cholesterol was unrelated to zeaxanthin plus lutein among supplement users; and 3) LDL cholesterol was unrelated to {alpha}-carotene among supplement users. The model 4 coefficients for the tocopherols were highest with VLDL cholesterol, and those for HDL and LDL cholesterol followed. Except for lycopene in the supplement nonusers, HDL cholesterol was more closely associated than was LDL cholesterol with each of the carotenoid concentrations. The association of VLDL cholesterol with carotenoids varied across antioxidants. VLDL cholesterol had a significant inverse association with ß-cryptoxanthin and ß-carotene among supplement nonusers. Lycopene had a significant positive association with VLDL cholesterol among both supplement users and nonusers. Among supplement users, ß-cryptoxanthin and {alpha}- and ß-carotene had a significant inverse association with VLDL cholesterol. Thus, the specific lipoprotein moieties varied in their relations with the various antioxidants.

In predicting {alpha}-tocopherol, regression coefficients were higher in the supplement nonusers than in the users (Table 2Go), eg, 2.99 and 2.86, respectively, for LDL in model 4. Slightly higher coefficients for LDL and HDL for all other antioxidants, with minor exceptions, were found in supplement nonusers than in users. These exceptions included the HDL coefficients for lycopene and ß-carotene, which were higher in supplement users than in nonusers. The ratios of coefficients (LDL in model 4) for {alpha}- and ß-carotene were more than slightly higher, at 3.22- and 1.77-fold, respectively, in supplement nonusers than in supplement users.

The use of apo A and apo B-100 did not improve the overall R2. The apolipoprotein combination yielded coefficients that were very similar to those of LDL alone (model 2) and smaller than those for cholesterol alone (model 1) or for a combination of lipoproteins (models 3 and 4 in Table 2Go). In addition, the inclusion of apo A and apo B-100 with the model containing LDL, HDL, and VLDL cholesterol only marginally improved R2 as compared with the simpler model 4 (data not shown).

Longitudinal regression analyses
Serum antioxidant levels were measured in 1875 supplement nonusers at both years 0 and 7 and in 537 supplement nonusers at both years. Concentrations of tocopherols and carotenoids increased, except that ß-cryptoxanthin in both groups and zeaxanthin plus lutein in supplement users did not change (Table 3Go). Serum antioxidant within-person concentrations increased in proportion to an increase in plasma lipid levels in both supplement nonusers and supplement users (model 5, Table 2Go), which indicated an effect of lipids on antioxidant concentrations. Among supplement nonusers, each lipoprotein was a significant independent predictor, with minor exceptions. These exceptions included VLDL cholesterol for ß-cryptoxanthin and lycopene, HDL cholesterol for ß-carotene, and all lipoproteins for {alpha}-carotene. Among the supplement users, the results indicated similar but less pronounced relations. These findings identified changes in lipoprotein concentrations as determinants of antioxidant concentrations over the course of a longitudinal epidemiologic study.


View this table:
[in this window]
[in a new window]
 
TABLE 3 . Changes in cholesterol and antioxidant vitamin concentrations from year 0 to year 7 in participants of the CARDIA study who consistently used or did not use vitamin supplements1
 
Application of adjustment formulas
In the comparison of models 1–4, model 4 generally accounted for significantly more of the variation in antioxidant concentrations than did the other models. This finding indicated that each of the lipoprotein moieties independently influenced antioxidant concentrations. Although the contribution of HDL and calculated LDL cholesterol concentrations may be trivial in small populations, the choice of model 3 rather than model 4 or 5 should be considered carefully. Two models, 4 and 5, contain each of the lipoprotein moieties and provide a basis for adjustment. It is important that model 4 is based on the measurement of between-subject change and that model 5 is based on the measurement of within-subject change. A comparison of the regression coefficients from model 4 and model 5 found a statistically significant difference (P < 0.01) between the coefficients of these models (Table 2Go) for all antioxidants except zeaxanthin (ie, 6 of the 7 antioxidants), albeit small differences in absolute terms in several instances. This finding indicated that the coefficients in model 4 were influenced by the history (unknown prior influences) of this population. Thus, the model 4 coefficients may be slightly less predictive of antioxidant concentrations in populations other than the population of origin. Model 5, on the other hand, was based on known changes in antioxidant concentrations with known changes in lipoprotein concentrations and is not dependent on the prestudy history of the population. In the model 5 analysis, each subject acts as his or her own control. Thus, if an equation from this report is used, model 5 is recommended for prediction of the influence of blood lipids on antioxidant concentrations in other populations. Alternatively, regression coefficients can be developed for a given population with the inclusion of LDL, HDL, and VLDL cholesterol in any regression equation involving lipid-soluble antioxidant vitamins.


    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Several previous studies showed that blood lipids can confound the interpretation of blood antioxidant concentrations and that lipid-adjusted antioxidant concentrations are more sensitive indicators of antioxidant status, intake, and risk of disease than are unadjusted antioxidant concentrations (1621, 43). Those studies used selective measures of blood lipids in their adjustments and thus represent an incomplete adjustment for the influence of blood lipids. A more comprehensive approach is taken in the current study, which considered all major lipids in plasma, as defined by the major circulating lipoproteins. The results have identified lipoproteins that influence blood antioxidant concentrations, described the extent of this influence in a human population, and compared several models of lipid adjustment.

Results of the current study show statistically significant linear relations between blood fat-soluble antioxidant and lipoprotein concentrations. These associations were found in cross-sectional observations between people, and they persisted through the evaluation of changes in antioxidant and lipoprotein concentrations with time, ie, when based on within-person longitudinal changes over a 7-y period, which strongly suggests that blood lipid influences antioxidant concentrations. In general, the participants who had increased blood lipid concentrations also had increased serum antioxidant levels and vice versa. In contrast, the ingestion of additional antioxidant vitamins in the form of supplements had little, if any, apparent influence on plasma total or lipoprotein cholesterol levels.

A model with independent adjustments for each major lipoprotein (LDL, HDL, and VLDL) accounted for as much or more variance (highest R2) in antioxidant concentrations that was due to changes in blood lipid concentrations than did models with total cholesterol or subsets of the lipoproteins only. This finding indicates that lipoproteins individually provide unique contributions toward the concentrations of antioxidants. For some antioxidants, the additional contribution of HDL and LDL may be small relative to that in model 3 (cholesterol and VLDL only).

In almost all cases, each lipoprotein particle was related in a positive manner to antioxidant concentrations. Exceptions were inverse rather than positive associations of VLDL with lycopene, ß-cryptoxanthin, {alpha}-carotene, and ß-carotene. Similar results were described in a previous report (18). These inverse associations may be a result of dietary patterns associated with hypertriglyceridemia. Hypertriglyceridemia has been linked with high intakes of fat and simple carbohydrates (44) and low intakes of fruits and vegetables, the primary sources of carotenoids. This pattern of intake could yield low antioxidant and high VLDL concentrations in blood. In addition, the conversion of ß-cryptoxanthin, {alpha}-carotene, and ß-carotene—primary sources of vitamin A—to vitamin A in the presence of low intakes may further lower their concentrations and contribute toward an inverse association as compared with other carotenoids. Unmeasured confounding is a possible limitation of all observational studies and could potentially influence coefficients of the equations. However, the general similarity of coefficients in the within-subject and between-subject equations (models 4 and 5), despite a statistically significant difference between the equations, suggests the absence of significant confounding for the coefficients in the models and the applicability of these findings to a larger population.

The pattern of association between lipoproteins and antioxidants varied for tocopherols and carotenoids. Tocopherols had high coefficients (an indicator of concentration in the particles) for VLDL, followed by HDL and then LDL. In contrast, all of the carotenoids involved a high HDL coefficient followed by LDL coefficients and a negative and/or statistically nonsignificant coefficient for VLDL particles. These unique patterns of distribution may be a result of antioxidant solubility and routes of absorption, of lipoprotein metabolism, and of the activity of transport proteins. Tocopherols are readily absorbed, transported via the lymph system into the circulation, and taken up by the liver. Hepatic tocopherols bind to the {alpha}-tocopherol transfer protein (45). This protein has a central role in the packaging of tocopherols in VLDL and regulation of blood tocopherol concentrations, because it preferentially identifies the {alpha} form of tocopherol and tends to exclude other forms of tocopherol from blood (46). The VLDL particles are metabolized to intermediate-density lipoprotein and then LDL particles with the retention of a small portion of their original {alpha}-tocopherol and carotenoids (47). HDL particles play a key role in the accumulation and exchange of {alpha}-tocopherol from other lipoproteins and tissues. These exchanges can occur through thermodynamic partitioning (diffusion) between particles (48, 49). Overall, {alpha}-tocopherol is shuttled in a specific manner into lipoproteins. On the other hand, no transport proteins have been reported for the carotenoids. The carotenoids may be distributed primarily on the basis of thermodynamic partitioning rather than being directed into VLDL and specific transport protein routes. Some, but not all, reports have found the absorption and transport of carotenoids via the portal vein rather than via the lymph system as occurs with tocopherols (50), which indicates a less specific path of distribution.

Despite the high apparent concentration (reflected in the coefficients) of tocopherol in VLDL particles, these particles are not a large contributor to total serum tocopherol concentrations. A short half-life and low concentration limit the amount of total tocopherol in VLDL particles. Their contribution to total serum tocopherol concentration can be estimated by multiplying the mean VLDL cholesterol concentration (in mmol/L) by its coefficient and comparing this value to the mean tocopherol concentration. Similar computations performed with carotenoids are consistent with fractionation studies: most circulating carotenoids are distributed between LDL and HDL particles, with a small amount in VLDL particles (51). The polar carotenoids are generally more concentrated in HDL particles than in LDL particles, whereas hydrocarbon carotenoids are shifted further toward LDL particles than are the polar carotenoids (52).

Elevated concentrations of antioxidants among supplement users may reflect higher intakes of vitamin E and ß-carotene and a sparing action on other antioxidants, thereby protecting them from oxidation. Although only 6 subjects explicitly reported ß-carotene supplementation, more subjects probably were ingesting it, given that it is generally the source of vitamin A in vitamin A supplements. In addition, supplement users may be more health conscious; they report consuming more servings of fruits and vegetables than do supplement nonusers in some populations (53). The particular pattern of food intake by supplement users apparently would not include good sources of {gamma}-tocopherol and lycopene, such as meat and pasta dishes (54).

Standardization is particularly useful for the most amphipathic antioxidants ({alpha}-tocopherol, {gamma}-tocopherol, and zeaxanthin plus lutein) and lycopene. However, lipid adjustment may be beneficial for some of the other antioxidants (ß-cryptoxanthin and ß-carotene) in certain situations. These include well-controlled feeding studies, cholesterol-lowering studies, and intervention studies wherein small changes of antioxidant concentrations may be important markers of status or wherein lipid-lowering interventions can mask the true changes in antioxidant concentrations.

The use of total cholesterol or total cholesterol and triacylglycerol for standardization can be a suitable second choice and is less costly than performing a lipoprotein profile. The use of LDL alone or apolipoproteins had marginal value in standardizing the fat-soluble antioxidant concentrations.


    ACKNOWLEDGMENTS
 
PH and XY performed the data and statistical analyses; CP performed the chemical analysis and data collection for all antioxidant measurements; DJ oversaw the statistical analysis and study design and aided in writing the manuscript; and MG provided the conceptual basis of the study, oversaw most aspects of the project, and wrote the final manuscript.


    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Traber MG. Vitamin E. In: Shils ME, Olson JA, Shike M, Ross AC, eds. Modern nutrition in health and disease. 9th ed. Baltimore: Williams & Wilkins, 1999:347–62.
  2. Olson JA. Carotenoids. In: Shils ME, Olson JA, Shike M, Ross AC, eds. Modern nutrition in health and disease. 9th ed. Baltimore: Williams & Wilkins, 1999:525–42.
  3. McCall MR, Frei B. Can antioxidant vitamins materially reduce oxidative damage in humans? Free Radic Biol Med 1999;26:1034–53.[Medline]
  4. Salonen JT, Nyyssonen K, Salonen R, et al. Lipoprotein oxidation and progression of carotid atherosclerosis. Circulation 1997;95:840–5.[Abstract/Free Full Text]
  5. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993;328:1444–9.[Abstract/Free Full Text]
  6. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993;328:1450–6.[Abstract/Free Full Text]
  7. Enstrom JE, Kanim LE, Klein MA. Vitamin C intake and mortality among a sample of the United States population. Epidemiology 1992;3:194–202.[Medline]
  8. Peto R, Doll R, Buckley JD, Sporn MB. Can dietary beta-carotene materially reduce human cancer rates? Nature 1981;290:201–8.[Medline]
  9. Ziegler RG. A review of epidemiological evidence that carotenoids reduce the risk of cancer. J Nutr 1989;119:116–22.
  10. ATBC Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330:1029–35.[Abstract/Free Full Text]
  11. Stephens NG, Parsons A, Schofield PM, et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347:781–6.[Medline]
  12. Azen SP, Qian D, Mack WJ, et al. Effect of supplementary antioxidant vitamin intake on carotid arterial wall intima-media thickness in a controlled clinical trial of cholesterol lowering. Circulation 1996;94:2369–72.[Abstract/Free Full Text]
  13. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145–53.[Abstract/Free Full Text]
  14. Horwitt MK, Harvey CC, Dahm CH, Searcy MT. Relationship between tocopherol and serum lipid levels for determination of nutritional adequacy. Ann N Y Acad Sci 1972;203:223–35.[Medline]
  15. Stryker WS, Kaplan LA, Stein EA, Stampfer MJ, Sober A, Willett WC. The relation of diet, cigarette smoking, and alcohol consumption to plasma beta-carotene and alpha-tocopherol levels. Am J Epidemiol 1988:127:283–96.[Abstract/Free Full Text]
  16. Sokol RJ, Heubi JE, Iannaccone ST, Bove KE, Balistreri WF. Vitamin E deficiency with normal serum vitamin E concentrations in children with chronic cholestasis. N Engl J Med 1984;310:1209–12.[Abstract]
  17. Sokol RJ, Balistreri WF, Hoofnagle JH, Jones EA. Vitamin E deficiency in adults with chronic liver disease. Am J Clin Nutr 1985;41:66–72.[Abstract/Free Full Text]
  18. Ascherio A, Stampfer MJ, Colditz GA, Rimm EB, Litin L, Willett WC. Correlations of vitamin A and E intakes with the plasma concentrations of carotenoids and tocopherols among American men and women. J Nutr 1992;122:1792–801.
  19. Campbell D, Gross MD, Martini M, Grandits G, Slavin J, Potter J. Plasma carotenoids as biomarkers of vegetable and fruit Intake. Cancer Epidemiol Biomarkers Prev 1994;3:493–500.[Abstract]
  20. Iribarren C, Folsom AR, Jacobs DR Jr, Gross MD, Belcher JD, Eckfeldt JH. Association of serum vitamin levels, LDL susceptibility to oxidation, and autoantibodies against MDA-LDL with carotid atherosclerosis. The ARIC Study Investigators. Arterioscler Thromb Vasc Biol 1997;17:1171–7.[Abstract/Free Full Text]
  21. Gey KF, Puska P. Plasma vitamin E and A inversely correlated to mortality from ischemic heart disease in cross-cultural epidemiology. Ann N Y Acad Sci 1989;570:268–82.[Medline]
  22. Spencer AP, Carson DS, Crouch MA. Vitamin E and coronary artery disease. Arch Intern Med 1999;159:1313–20.[Abstract/Free Full Text]
  23. Riemersma RA, Wood DA, Macintyre CCA, Elton RA, Gey KF, Oliver MF. Risk of angina pectoris and plasma concentrations of vitamins A, C, and E and carotene. Lancet 1991;337:1–5.[Medline]
  24. Ford ES, Will JC, Bowman BA, Narayan KMV. Diabetes mellitus and serum carotenoids: findings from the third National Health and Nutrition Examination Survey. Am J Epidemiol 1999;149:168–76.[Abstract/Free Full Text]
  25. Ford ES, Giles WH. Serum vitamins, carotenoids, and angina pectoris: findings from the National Health and Nutrition Examination Survey III. Ann Epidemiol 2000;10:106–16.[Medline]
  26. Willett W. Nutritional epidemiology. New York: Oxford University Press, 1990.
  27. Erdman JW, Bierer TL, Gugger ET. Absorption and transport of carotenoids. Ann N Y Acad Sci 1993;691:76–85.[Medline]
  28. Behrens WA, Thompson JN, Madere R. Distribution of {alpha}-tocopherol in human plasma lipoproteins. Am J Clin Nutr 1982;35:691–6.[Abstract/Free Full Text]
  29. von Herbay A, de Groot H, Hegi U, Stremmel W, Strohmeyer G, Sies H. Low vitamin E concentration in plasma of patients with alcoholic liver disease, hemochromatosis and Wilson’s disease. J Hepatol 1994;20:41–6.[Medline]
  30. Comstock GW, Bush TL, Helzlsouer K. Serum retinol, beta-carotene, vitamin E, and selenium as related to subsequent cancer of specific sites. Am J Epidemiol 1992;135:115–21.[Abstract/Free Full Text]
  31. Thurnham DI, Davies JA, Crump BJ, Situnayake RD, Davis M. The use of different lipids to express serum tocopherol: lipid ratios for the measurement of vitamin E status. Ann Clin Biochem 1986;23:514–20.
  32. Friedman GD, Cutter GR, Donahue RP, et al. CARDIA: study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol 1988;41:1105–16.[Medline]
  33. Donahue RP, Jacobs DR Jr, Sidney S, Wagenknecht LE, Albers JJ, Hulley SB. Distribution of lipoproteins and apolipoproteins in young adults. The CARDIA Study. Arteriosclerosis 1989;9:656–64.[Abstract/Free Full Text]
  34. Jacobs DR Jr, Hannan PJ, Wallace D, Liu K, Williams OD, Lewis CE. Interpreting age, period and cohort effects in plasma lipids and serum insulin using repeated measures regression analysis: the CARDIA Study. Stat Med 1999;18:655–79.[Medline]
  35. Smith DE, Thompson JK, Raczynski JM, Hilner JE. Body image among men and women in a biracial cohort: the CARDIA Study. Int J Eat Disord 1999;25:71–82.[Medline]
  36. Warnick GR. Enzymatic methods for quantification of lipoprotein lipids. Methods Enzymol 1986;129:101–23.[Medline]
  37. Warnick GR, Benderson J, Albers JJ. Dextran sulphate-Mg2+ precipitation procedure for quantification of high-density-lipoprotein cholesterol. Clin Chem 1982;28:1379–88.[Free Full Text]
  38. Friedewald WT, Levy RI, Friederickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502.[Abstract]
  39. Albers JJ, Adolphson JL. Comparison of commercial kits for apoprotein A1 and apoprotein B with standardized apoprotein A1 and B radioimmunoassays performed at the Northwest Lipid Research Center. J Lipid Res 1988;29:102–8.[Abstract]
  40. Bieri JG, Brown ED, Smith JC. Determination of individual carotenoids in human plasma by high performance chromatography. J Liquid Chromatogr 1985;8:473–84.
  41. Craft NE, Brown ED, Smith JC Jr. Effects of storage and handling conditions on concentrations of individual carotenoids, retinol, and tocopherol in plasma. Clin Chem 1988;34:44–8.[Abstract/Free Full Text]
  42. Gross MD, Prouty CB, Jacobs DR Jr. Stability of carotenoids and tocopherol during blood collection and processing procedures. Clin Chem 1995;41:943–4.[Free Full Text]
  43. Jordan P, Brubacher D, Moser U, Stähelin HB, Gey KF. Vitamin E and vitamin A concentrations in plasma adjusted for cholesterol and triglycerides by multiple regression. Clin Chem 1995;41:924–7.[Abstract/Free Full Text]
  44. Preuss HG, Gondal JA, Lieberman S. Association of macronutrients and energy intake with hypertension. J Am Coll Nutr 1996;15:21–35.[Abstract]
  45. Traber MG, Sokol RJ, Burton GW, et al. Impaired ability of patients with familial isolated vitamin E deficiency to incorporate alpha-tocopherol into lipoproteins secreted by the liver. J Clin Invest 1990;85:397–407.
  46. Behrens WA, Madère R. Alpha- and gamma tocopherol concentrations in human serum. J Am Coll Nutr 1986;5:91–6.[Abstract]
  47. Brubacher G, Stähelin HB, Vuilleumier JP. Relation between beta-lipoprotein concentration in serum and plasma vitamin E concentration. A contribution to the question of the estimation of the vitamin E status in man. Int J Vit Nutr Res 1974;44:521–6 (in German).
  48. Massey JB. Kinetics of transfer of alpha-tocopherol between model and native plasma lipoproteins. Biochim Biophys Acta 1984;793:387–92.[Medline]
  49. Traber MG, Lane JC, Lagmay N, Kayden HJ. Studies on the transfer of tocopherol between lipoproteins. Lipids 1992;27:657–63.[Medline]
  50. Kowalewski K, Henrotin E, Van Geertruyden J. Role of portal and lymphatic circulation in the transport of orally administered carotene. Acta Gastroenterol Belg 1951;14:7–15.
  51. Krinsky NI, Cornwell DG, Oncley JL. The transport of vitamin A and carotenoids in human plasma. Arch Biochem Biophys 1958;73:233–46.[Medline]
  52. Bjornson LK, Kayden HJ, Miller E, Moshell AN. The transport of alpha-tocopherol and beta-carotene in human blood. J Lipid Res 1976;17:343–52.[Abstract]
  53. Lyle BJ, Mares-Perlman JA, Klein BE, Klein R, Greger JL. Supplement users differ from nonusers in demographic, lifestyle, dietary and health characteristics. J Nutr 1998;128:2355–62.[Abstract/Free Full Text]
  54. Bauerfeind J. Tocopherols in foods. In: Machlin LJ, ed. Vitamin E: a comprehensive treatise. Basic and clinical nutrition. Vol 1. James WPT, Herman RH, Bray GA, eds. New York: Marcel Dekker, 1980:99–168.
Received for publication January 30, 2002. Accepted for publication May 30, 2002.




This article has been cited by other articles:


Home page
Diabetes CareHome page
K. Park, M. Gross, D.-H. Lee, P. Holvoet, J. H. Himes, J. M. Shikany, and D. R. Jacobs Jr.
Oxidative Stress and Insulin Resistance: The Coronary Artery Risk Development in Young Adults study
Diabetes Care, July 1, 2009; 32(7): 1302 - 1307.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
B. Thyagarajan, D. R. Jacobs Jr., J. J. Carr, O. Alozie, M. W. Steffes, P. Kailash, J. H. Hayes, and M. D. Gross
Factors Associated with Paraoxonase Genotypes and Activity in a Diverse, Young, Healthy Population: The Coronary Artery Risk Development in Young Adults (CARDIA) Study
Clin. Chem., April 1, 2008; 54(4): 738 - 746.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
T. Ohira, A. Hozawa, C. Iribarren, M. L. Daviglus, K. A. Matthews, M. D. Gross, and D. R. Jacobs Jr.
Longitudinal Association of Serum Carotenoids and Tocopherols with Hostility: The CARDIA Study
Am. J. Epidemiol., January 1, 2008; 167(1): 42 - 50.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
Y. L. Kim, D. R. Jacobs Jr., M. D. Gross, R. C. Bergan, P. H. Gann, K. Liu, and S. M. Gapstur
Associations of Serum Carotenoid Levels with Serum Insulin-like Growth Factor-I and Insulin-like Growth Factor Binding Protein-3 Levels in Black Men and White Men
Cancer Epidemiol. Biomarkers Prev., December 1, 2007; 16(12): 2781 - 2783.
[Full Text] [PDF]


Home page
J. Nutr.Home page
D. Waters, R. M. Clark, C. M. Greene, J. H. Contois, and M. L. Fernandez
Change in Plasma Lutein after Egg Consumption Is Positively Associated with Plasma Cholesterol and Lipoprotein Size but Negatively Correlated with Body Size in Postmenopausal Women
J. Nutr., April 1, 2007; 137(4): 959 - 963.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
A. Hozawa, D. R. Jacobs Jr., M. W. Steffes, M. D. Gross, L. M. Steffen, and D.-H. Lee
Relationships of Circulating Carotenoid Concentrations with Several Markers of Inflammation, Oxidative Stress, and Endothelial Dysfunction: The Coronary Artery Risk Development in Young Adults (CARDIA)/Young Adult Longitudinal Trends in Antioxidants (YALTA) Study
Clin. Chem., March 1, 2007; 53(3): 447 - 455.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
E. S Ford, R. L Schleicher, A. H Mokdad, U. A Ajani, and S. Liu
Distribution of serum concentrations of {alpha}-tocopherol and {gamma}-tocopherol in the US population.
Am. J. Clinical Nutrition, August 1, 2006; 84(2): 375 - 383.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
A. Hozawa, D. R. Jacobs Jr., M. W. Steffes, M. D. Gross, L. M. Steffen, and D.-H. Lee
Associations of Serum Carotenoid Concentrations with the Development of Diabetes and with Insulin Concentration: Interaction with Smoking: The Coronary Artery Risk Development in Young Adults (CARDIA) Study
Am. J. Epidemiol., May 15, 2006; 163(10): 929 - 937.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
R. M. Clark, K. L. Herron, D. Waters, and M. L. Fernandez
Hypo- and Hyperresponse to Egg Cholesterol Predicts Plasma Lutein and {beta}-Carotene Concentrations in Men and Women
J. Nutr., March 1, 2006; 136(3): 601 - 607.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
R. S Bruno, S. W Leonard, S.-i. Park, Y. Zhao, and M. G Traber
Human vitamin E requirements assessed with the use of apples fortified with deuterium-labeled {alpha}-tocopheryl acetate
Am. J. Clinical Nutrition, February 1, 2006; 83(2): 299 - 304.
[Abstract] [Full Text] [PDF]


Home page
J. Histochem. Cytochem.Home page
A. Lindqvist, Y.-G. He, and S. Andersson
Cell Type-specific Expression of {beta}-Carotene 9',10'-Monooxygenase in Human Tissues
J. Histochem. Cytochem., November 1, 2005; 53(11): 1403 - 1412.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
V. Ganji and M. R. Kafai
Population Determinants of Serum Lycopene Concentrations in the United States: Data from the Third National Health and Nutrition Examination Survey, 1988-1994
J. Nutr., March 1, 2005; 135(3): 567 - 572.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
R. S Bruno, R. Ramakrishnan, T. J Montine, T. M Bray, and M. G Traber
{alpha}-Tocopherol disappearance is faster in cigarette smokers and is inversely related to their ascorbic acid status
Am. J. Clinical Nutrition, January 1, 2005; 81(1): 95 - 103.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
M. Gross, M. Steffes, D. R. Jacobs Jr, X. Yu, L. Lewis, C. E. Lewis, and C. M. Loria
Plasma F2-Isoprostanes and Coronary Artery Calcification: The CARDIA Study
Clin. Chem., January 1, 2005; 51(1): 125 - 131.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
D.-H. Lee, M. D. Gross, and D. R. Jacobs Jr
Association of Serum Carotenoids and Tocopherols with {gamma}-Glutamyltransferase: The Cardiovascular Risk Development in Young Adults (CARDIA) Study
Clin. Chem., March 1, 2004; 50(3): 582 - 588.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gross, M.
Right arrow Articles by Jacobs, D. R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gross, M.
Right arrow Articles by Jacobs, D. R, Jr
Agricola
Right arrow Articles by Gross, M.
Right arrow Articles by Jacobs, D. R


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS